MDxHealth CEO acquires company shares worth $80,000

Published 07/03/2025, 14:34
MDxHealth CEO acquires company shares worth $80,000

MDxHealth SA (NASDAQ:MDXH), a company specializing in medical laboratory services with a market capitalization of $76 million, disclosed that Michael McGarrity, the firm’s Chief Executive Officer and Board member, purchased 50,000 ordinary shares on Thursday. The total investment made by McGarrity amounted to approximately $80,000, as per the report filed with the U.S. Securities and Exchange Commission (SEC). The purchase comes as the stock trades near its 52-week low of $1.55, having declined 12% in the past week.

The transaction took place on March 6, 2025, and was publicly announced the following day. The company, headquartered in Herstal, Belgium, emphasized that this information is furnished and not filed for the purposes of the Securities Exchange Act of 1934, nor is it incorporated by reference in any other SEC filings.

The CEO’s acquisition of shares is not typically mandated to be disclosed except in specific circumstances such as in the company’s Annual Report on Form 20-F. McGarrity has not committed to reporting further transactions unless legally required.

This press release statement serves as the basis for this news article and provides the latest verified information regarding the CEO’s recent investment in MDxHealth. The company has not provided any additional details about the purchase or its potential implications for investors or the market.

In other recent news, MDxHealth SA ADR reported impressive financial results for the fourth quarter of 2024. The company surpassed earnings expectations with an earnings per share (EPS) of -$0.14, outperforming the anticipated -$0.19. Revenue also exceeded forecasts, reaching $24.7 million compared to the expected $22.9 million. This represents a significant year-over-year growth of 28%, driven by increased billable volume and strong test performance.

MDxHealth’s operating loss decreased by 27% to $4.6 million, while the net loss fell by 36% to $6.8 million, indicating improved financial health. Furthermore, the company achieved a 68% improvement in adjusted EBITDA, which was negative $1.4 million for the quarter. Looking ahead, MDxHealth aims to achieve adjusted EBITDA positivity by the first or second quarter of 2025, supported by a revenue guidance of $108-110 million for the year.

Analysts have noted the company’s strong performance, with firms like Lake Street and William Blair showing interest in MDxHealth’s growth trajectory. The company remains confident in its sustainable growth, despite conservative expectations for its germline testing revenue. MDxHealth’s strategic focus on operating profitability and market conversion continues to drive its financial success in the competitive urology diagnostics market.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.